Related Experiment Video
Updated: Jun 12, 2026

Oral Administration of Rotenone using a Gavage and Image Analysis of Alpha-synuclein Inclusions in the Enteric Nervous System
Published on: October 26, 2010
Transdermal rotigotine for the perioperative management of Parkinson's disease
Ullrich Wüllner1, Jan Kassubek, Per Odin
1Department of Neurology, University Bonn, Sigmund-Freud-Strasse 25, 53105, Bonn, Germany. wuellner@uni-bonn.de
Abstract:
Continuous delivery of antiparkinsonian medication during a perioperative period is desirable to avoid 'off'-symptom complications in surgical patients with concomitant Parkinson's disease (PD). Fourteen PD patients undergoing surgery under general anesthesia were switched from oral dopaminergic medication to transdermally delivered 24-h rotigotine (median dose 12 mg/24 h) for the perioperative period. Rotigotine treatment was considered feasible by patients, their anesthesiologists and neurologists with good control of PD symptoms and easy switching and re-switching of PD medication.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview
Transdermal Drug Delivery Systems
Parkinson Disease l: Introduction
Parkinson Disease ll: Pathophysiology
Direct-Acting Cholinergic Agonists: Therapeutic Uses